### Furosemide

**Section:** 16. Diuretics

<table>
<thead>
<tr>
<th><strong>Indication</strong></th>
<th>Anuria or oliguria</th>
<th><strong>ICD11 code:</strong> MF51</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INN</strong></td>
<td>Furosemide</td>
<td></td>
</tr>
<tr>
<td><strong>Medicine type</strong></td>
<td>Chemical agent</td>
<td></td>
</tr>
<tr>
<td><strong>List type</strong></td>
<td>Core</td>
<td></td>
</tr>
</tbody>
</table>

**Additional notes**
The square box applies only to the listing of furosemide on the EML.

**Formulations**
- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
- Oral > Liquid: 20 mg per 5 mL (EMLc)
- Oral > Solid: 40 mg; 10 mg (EMLc); 20 mg (EMLc)

**EML status history**
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 2007 (TRS 950)
- Changed in 2021 (TRS 1035)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- Bumetanide (ATC codes: C03CA02)
- Torasemide (ATC codes: C03CA04)

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**
- Furosemide

**DrugBank**
- Furosemide

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended bumetanide and torasemide be specified as therapeutic alternatives under the square box listing for furosemide on the EML. The square box does not apply to the listing of furosemide on the EMLc.